ETX.L Regulatory News (ETX)

e-Therapeutics plc (AIM: ETX)

Notification of Full Year Results Date

Oxford and Newcastle, UK, 25 April 2014 - e-Therapeutics plc (AIM: ETX), the drug discovery and development company with a proprietary platform in network pharmacology, will be announcing its full year results for the period ended 31 January 2014 on Monday, 12 May 2014.

A group analyst briefing will be held on the same day at 09:30am BST at Instinctif Partners' offices at 65 Gresham Street, London EC2V 7NQ. Analysts who wish to participate should either contact Instinctif Partners on +44 (0)20 7457 2020 or email e-therapeutics@instinctif.com to register.

- Ends -

About e-Therapeutics

e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is focused in cancer and disorders of the nervous system. e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.

Contacts:

e-Therapeutics plc

Steve Medlicott

Tel: +44 (0) 1993 880000

www.etherapeutics.co.uk 

Panmure Gordon (UK) Limited

Fred Walsh / Duncan Monteith

Tel: +44 (0) 20 7886 2500

www.panmure.com

Instinctif Partners

Melanie Toyne Sewell / Stefanie Bacher / Rebecca Caygill

Tel: +44 (0) 20 7457 2020

Email: e-therapeutics@instinctif.com

CommStrat Group (US)

Ted Agne

Tel: (+1) 781 631 3117

Email: edagne@comstratgroup.com